
Swiss pharmaceutical group Helsinn has entered an agreement with MEI Pharma over the licensing, development and commercialisation of Pracinostat (SB939) …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

